Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 2.98 as of 2026-10-06T16:27:16.765Z.
Consensus retrieved: 2026-10-06T12:56:18.993Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:27:16.765Z.
Quote observation: 2026-10-06T16:25:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d19fbcbfe88228e771d1365594a8990eb95a9f33d90bd822f782d755a125eeec
Forward PE Ratio (2.98) = Dated Quote Price ($3.64) / Consensus Forward EPS ($1.22)
FORWARD PE RATIO
2.98
SECTOR MEDIAN · HEALTHCARE
19.48
median of 177 covered companies
CURRENT VS SECTOR MEDIAN
-84.70%
vs the sector median at left
Ironwood Pharmaceuticals, Inc.
Market Cap
$599.19M
Forward PE Ratio
2.98
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Ironwood Pharmaceuticals, Inc. (IRWD) | $599.19M | 2.98 |
| AngioDynamics, Inc. (ANGO)vs › | $605.73M | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $593.40M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $588.16M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $574.01M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $633.33M | N/A |
| CorMedix Inc. (CRMD)vs › | $566.30M | 14.58 |
| Prime Medicine, Inc. (PRME)vs › | $633.99M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $564.94M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $636.13M | N/A |
Trailing P/E
4.7
reported TTM EPS
Forward P/E
3.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.22 implies +58.4% EPS growth vs the reported trailing $0.77.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
At the dated quote price of $3.64, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.22 | $1.18 – $1.25 | 2 | 3.0x |
| 2027-12-31 | $1.32 | $1.27 – $1.35 | 2 | 2.8x |
| 2028-12-31 | $1.43 | $1.38 – $1.46 | 1 | 2.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
